Low GGH Expression in Colorectal Cancer with CIMP+
Author Information
Author(s): Kawakami K, Ooyama A, Ruszkiewicz A, Jin M, Watanabe G, Moore J, Oka T, Iacopetta B, Minamoto T
Primary Institution: Kanazawa University
Hypothesis
Is there a specific mRNA expression pattern for folate- and nucleotide-metabolising enzymes in CIMP+ colorectal cancer?
Conclusion
Low expression of γ-glutamyl hydrolase (GGH) is associated with the CpG island methylator phenotype in colorectal cancer.
Supporting Evidence
- Low GGH expression was consistently associated with CIMP+ features in both Australian and Japanese colorectal cancer cohorts.
- Only 5.6% of CIMP+ tumors showed hypermethylation of the GGH promoter, indicating it does not account for low expression.
- GGH expression was significantly lower in CIMP+ colorectal cancer compared to CIMP−.
Takeaway
This study found that colorectal cancer with a specific genetic change has lower levels of a protein called GGH, which might affect how the cancer grows.
Methodology
mRNA levels for 17 genes were measured by real-time RT-PCR in colorectal cancer samples, and CIMP+ status was determined by methylation-specific PCR.
Potential Biases
Potential biases may arise from the selection of samples and the methods used for gene expression analysis.
Limitations
The study's findings may not be generalizable due to the specific populations studied (Australian and Japanese cohorts).
Participant Demographics
Participants included colorectal cancer patients from Australia and Japan.
Statistical Information
P-Value
0.023
Confidence Interval
95% CI: 0.51–0.95
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website